- NCIt
- C2960
Loading cancer entity…
Loading cancer entity…
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05087849 | Intralesional HPV Vaccine for Condylomata | completed | Phase 1 / Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02462187 | Topical NVN1000 for the Treatment of External Genital and Perianal Warts | completed | Phase 2 | 108 | Novan, Inc.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT01796821 | Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) | completed | Phase 2 | 138 | G&E Herbal Biotechnology Co., LTDINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02724254 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients |
Data updated 22 days agoSource updated Oct 2, 2025source: clinicaltrials
| completed |
| Phase 2 |
| 218 |
| VaxartINDUSTRY |
| 4 |
| Jul 20, 2018 |
| clinicaltrials |
| NCT00520598 | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) | completed | Phase 2 | 511 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 26, 2015 | clinicaltrials |
| NCT00551187 | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | completed | Phase 2 | 620 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT01555112 | Safety and Efficacy Study to Test Topical AS101 for External Genital Warts | completed | Phase 1 / Phase 2 | 12 | BioMAS LtdINDUSTRY | 1 | Aug 15, 2013 | clinicaltrials |